GSK
GSK plc
There isn't enough reported data to score GSK yet.
GSK Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Healthy |
GSK's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
GSK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.7x | $16.03 | -68% |
| Fair | 14x | $25.09 | -50% |
| Current | 14x | $50.64 | — |
| Expensive | 16x | $29.98 | -41% |
Historical ranges are pointers, not guarantees.
GSK's PE is 14x, but its earnings don't support one, so it isn't a reliable read right now.
GSK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for GSK, with profitability improving.
GSK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $1.85 | +123% |
| Q4 2024 | $0.83 | -48% |
| Q4 2023 | $1.59 | -67% |
| Q4 2022 | $4.87 | +238% |
| Q4 2021 | $1.44 | -24% |
| Q4 2020 | $1.90 | +23% |
| Q4 2019 | $1.54 | +27% |
| Q4 2018 | $1.21 | +133% |
GSK earned $1.85 per share over the past year, up 28% from the year before.
GSK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $43.5B | +4.1% |
| Q4 2024 | $41.7B | +3.5% |
| Q4 2023 | $40.3B | +3.4% |
| Q4 2022 | $39B | -14% |
| Q4 2021 | $45.4B | 0% |
| Q4 2020 | $45.4B | +1% |
| Q4 2019 | $44.9B | +9.5% |
| Q4 2018 | $41B | +2.1% |
GSK's revenue is shrinking: $43.5B last quarter, down 4.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 24% | +6.1 points |
| Q4 2024 | 13% | -10 points |
| Q4 2023 | 22% | +1.6 points |
| Q4 2022 | 22% | +4.2 points |
| Q4 2021 | 18% | +4.6 points |
| Q4 2020 | 23% | +15 points |
| Q4 2019 | 21% | +1.7 points |
| Q4 2018 | 18% | N/A |
GSK's operating margin was 24% last quarter, up 6.1 points from the same quarter a year ago, near the top of its range since 2016.
GSK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $8.5B | +24% |
| Q4 2024 | $6.9B | -5.5% |
| Q4 2023 | $7.3B | -13% |
| Q4 2022 | $8.3B | -7.7% |
| Q4 2021 | $9B | -6% |
| Q4 2020 | $9.6B | +6.8% |
| Q4 2019 | $9B | -4.5% |
| Q4 2018 | $9.4B | +32% |
GSK's free cash flow has been positive every quarter since mid-2016: $30.9B over the past year, down 16% from the year before.
GSK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -25M shares |
| 1 year | +1.6% | +65M shares |
| 3 years | +110% | +2.2B shares |
GSK has 4.1B diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $1.8B |
| Q4 2016 | $5.3M |
| Q3 2016 | $16M |
GSK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 1.5x | Healthy |
| Q4 2024 | 2.0x | Moderate |
| Q4 2023 | 1.8x | Healthy |
| Q4 2022 | 2.2x | Moderate |
| Q4 2021 | 2.4x | Moderate |
| Q4 2020 | 2.1x | Moderate |
| Q4 2019 | 3.2x | Elevated |
| Q4 2018 | 3.1x | Elevated |
GSK's net debt is about 1.5 years of its operating earnings (EBITDA), down from 2.4 years a year ago.
GSK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.6 | Neutral |
| Stochastic | 55.5 | Neutral |
GSK's weekly RSI is 51 (neutral) and its Stochastic is 56 (neutral).
GSK PE vs Healthcare Sector
| Metric | GSK | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 47% below |
| PE % | 53 | 29 | 24 pts above |
GSK is trading at 14x earnings, a 47% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GSK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $49.2 | 2.9% above |
| 20 week MA | $50.4 | 0.4% above |
| 50 week MA | $51.9 | 2.4% below |
| 100 week MA | $45.5 | 11% above |
| 200 week MA | $41.7 | 21% above |
GSK's trend is mixed: it's above four of its five weekly moving averages, and 21% above its 200-week average.
GSK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $47.3 | $36.1 | -24% |
| 2021 | $36.1 | $43.8 | +21% |
| 2022 | $43.8 | $35.2 | -20% |
| 2023 | $35.2 | $37.1 | +5.2% |
| 2024 | $37.1 | $34.1 | -8% |
| 2025 | $34.1 | $49.1 | +44% |
| 2026 YTD | $49.1 | $50.6 | +3.2% |
GSK has finished lower in three of the last six years. It's up 3.2% so far in 2026.